Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

8.55
+0.43005.30%
Post-market: 8.570.0200+0.23%17:10 EDT
Volume:3.87M
Turnover:33.52M
Market Cap:885.64M
PE:-1.64
High:8.89
Open:8.45
Low:8.43
Close:8.12
Loading ...

Stock Track | Intellia Therapeutics Soars 7.70% in Pre-Market Following Evercore ISI's Buy Rating Reiteration

Stock Track
·
Yesterday

Stock Track | Intellia Therapeutics Soars 7.70% Pre-Market Following Evercore ISI's Buy Rating Reiteration

Stock Track
·
Yesterday

Intellia Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Yesterday

Evercore ISI Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
Yesterday

RBC Trims Price Target on Intellia Therapeutics to $30 From $32, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 May

Intellia Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
09 May

Intellia Therapeutics price target lowered to $10 from $14 at Citi

TIPRANKS
·
09 May

Bank of America Securities Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
09 May

Intellia Therapeutics: Hold Rating Amid Regulatory Challenges and Strategic Consolidation

TIPRANKS
·
09 May

BUZZ-U.S. STOCKS ON THE MOVE-Tapestry, Carvana, PPG Industries

Reuters
·
08 May

BUZZ-Intellia Therapeutics rises on narrower Q1 loss

Reuters
·
08 May

Stock Track | Intellia Therapeutics Soars 10.84% on Strong Q1 Results and Extended Cash Runway

Stock Track
·
08 May

Stock Track | Intellia Therapeutics Soars 5.49% Pre-market on Strong Q1 Results and Extended Cash Runway

Stock Track
·
08 May

Intellia Therapeutics Ended Q1 2025 With Approximately $707.1M In Cash, Cash Equivalents And Marketable Securities; Expected To Fund Operations Into 1H Of 2027

Benzinga
·
08 May

Intellia Therapeutics Q1 2025 EPS $(1.10) Beats $(1.27) Estimate, Sales $16.63M Beat $11.87M Estimate

Benzinga
·
08 May

Intellia Therapeutics Inc: Ended Q1 With About $707.1 Mln in Cash, Cash Equivalents & Marketable Securities

THOMSON REUTERS
·
08 May